inspiring medical recruitment Home: only medics - inspiring medical recruitment
Home About Us Clients Candidates Vacancies Training Resources Contact Us


Resources Home
Health News
Articles
Downloads
Links
Medical Dictionary
Pharmaceutical Terms

Resources

Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors

02/11/2007

Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors

Vera L Costa, Rui Henrique, Franclim R Ribeiro, Mafalda Pinto, Jorge Oliveira, Francisco Lobo, Manuel R Teixeiraand Carmen Jerónimo

Published: 23 July 2007

Abstract

Background
Aberrant promoter hypermethylation of cancer-associated genes occurs frequently during carcinogenesis and may serve as a cancer biomarker. In this study we aimed at defining a quantitative gene promoter methylation panel that might identify the most prevalent types of renal cell tumors.

Methods
A panel of 18 gene promoters was assessed by quantitative methylation-specific PCR (QMSP) in 85 primarily resected renal tumors representing the four major histologic subtypes (52 clear cell (ccRCC), 13 papillary (pRCC), 10 chromophobe (chRCC), and 10 oncocytomas) and 62 paired normal tissue samples. After genomic DNA isolation and sodium bisulfite modification, methylation levels were determined and correlated with standard clinicopathological parameters.

Results
Significant differences in methylation levels among the four subtypes of renal tumors were found for CDH1 (p = 0.0007), PTGS2 (p = 0.002), and RASSF1A (p = 0.0001). CDH1 hypermethylation levels were significantly higher in ccRCC compared to chRCC and oncocytoma (p = 0.00016 and p = 0.0034, respectively), whereas PTGS2 methylation levels were significantly higher in ccRCC compared to pRCC (p = 0.004). RASSF1A methylation levels were significantly higher in pRCC than in normal tissue (p = 0.035). In pRCC, CDH1 and RASSF1A methylation levels were inversely correlated with tumor stage (p = 0.031) and nuclear grade (p = 0.022), respectively.

Conclusion
The major subtypes of renal epithelial neoplasms display differential aberrant CDH1, PTGS2, and RASSF1A promoter methylation levels. This gene panel might contribute to a more accurate discrimination among common renal tumors, improving preoperative assessment and therapeutic decision-making in patients harboring suspicious renal masses.


Click here to download a pdf of the full article.

Return to Listing

Print this Page

©2006 only medics ltd

Home | Privacy Policy | Site Map